Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $3.32 billion. The enterprise value is $3.66 billion.
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, after market close.
Earnings Date | May 1, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RARE has 92.50 million shares outstanding. The number of shares has increased by 23.11% in one year.
Current Share Class | 92.50M |
Shares Outstanding | 92.50M |
Shares Change (YoY) | +23.11% |
Shares Change (QoQ) | +0.20% |
Owned by Insiders (%) | 3.59% |
Owned by Institutions (%) | 95.83% |
Float | 89.14M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 6.11 |
Forward PS | 5.21 |
PB Ratio | 13.70 |
P/TBV Ratio | 107.39 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 6.54 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 3.47.
Current Ratio | 2.37 |
Quick Ratio | 2.13 |
Debt / Equity | 3.47 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -8.50 |
Financial Efficiency
Return on equity (ROE) is -211.71% and return on invested capital (ROIC) is -28.12%.
Return on Equity (ROE) | -211.71% |
Return on Assets (ROA) | -22.37% |
Return on Invested Capital (ROIC) | -28.12% |
Return on Capital Employed (ROCE) | -46.23% |
Revenue Per Employee | $432,944 |
Profits Per Employee | -$439,863 |
Employee Count | 1,294 |
Asset Turnover | 0.37 |
Inventory Turnover | 19.62 |
Taxes
In the past 12 months, RARE has paid $1.60 million in taxes.
Income Tax | 1.60M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.22% in the last 52 weeks. The beta is 0.67, so RARE's price volatility has been lower than the market average.
Beta (5Y) | 0.67 |
52-Week Price Change | -19.22% |
50-Day Moving Average | 41.61 |
200-Day Moving Average | 47.10 |
Relative Strength Index (RSI) | 39.28 |
Average Volume (20 Days) | 736,111 |
Short Selling Information
The latest short interest is 4.81 million, so 5.20% of the outstanding shares have been sold short.
Short Interest | 4.81M |
Short Previous Month | 4.59M |
Short % of Shares Out | 5.20% |
Short % of Float | 5.40% |
Short Ratio (days to cover) | 6.08 |
Income Statement
In the last 12 months, RARE had revenue of $560.23 million and -$569.18 million in losses. Loss per share was -$6.29.
Revenue | 560.23M |
Gross Profit | -214.36M |
Operating Income | -535.97M |
Pretax Income | -586.86M |
Net Income | -569.18M |
EBITDA | -500.43M |
EBIT | -535.97M |
Loss Per Share | -$6.29 |
Full Income Statement Balance Sheet
The company has $610.03 million in cash and $910.01 million in debt, giving a net cash position of -$164.98 million or -$1.78 per share.
Cash & Cash Equivalents | 610.03M |
Total Debt | 910.01M |
Net Cash | -164.98M |
Net Cash Per Share | -$1.78 |
Equity (Book Value) | 262.30M |
Book Value Per Share | 2.76 |
Working Capital | 472.97M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$414.19 million and capital expenditures -$7.49 million, giving a free cash flow of -$421.68 million.
Operating Cash Flow | -414.19M |
Capital Expenditures | -7.49M |
Free Cash Flow | -421.68M |
FCF Per Share | -$4.56 |
Full Cash Flow Statement Margins
Gross margin is -38.26%, with operating and profit margins of -95.67% and -101.60%.
Gross Margin | -38.26% |
Operating Margin | -95.67% |
Pretax Margin | -101.31% |
Profit Margin | -101.60% |
EBITDA Margin | -89.33% |
EBIT Margin | -95.67% |
FCF Margin | n/a |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -23.11% |
Shareholder Yield | -23.11% |
Earnings Yield | -16.27% |
FCF Yield | -12.05% |
Dividend Details Analyst Forecast
The average price target for RARE is $95.93, which is 167.62% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $95.93 |
Price Target Difference | 167.62% |
Analyst Consensus | Strong Buy |
Analyst Count | 15 |
Revenue Growth Forecast (5Y) | 35.47% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -2.09 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -2.09 |
Piotroski F-Score | 4 |